AMS-2

AMS-2 is a preclinical monoclonal antibody developed by ZIP Zinc Therapeutics, a spin-out from Cardiff University. It is designed to target zinc transporter proteins, specifically those in the ZIP family, to inhibit the influx of zinc into cancer cells. Zinc is a critical micronutrient that supports various signaling pathways and metabolic processes essential for tumor cell proliferation and survival. By blocking these transporters, AMS-2 aims to disrupt the zinc-dependent mechanisms that drive tumor growth. The candidate is being investigated for the treatment of several aggressive and treatment-resistant malignancies, including triple-negative breast cancer, anti-hormone resistant breast cancer, colon cancer, prostate cancer, and melanoma.